11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 18; no. 4; pp. S43 - S44
Main Authors Majem, M., Forster, M.D., Krebs, M.G., Peguero, J., Clay, T.D., Felip, E., Iams, W., Roxburgh, P., de Spéville, B. Doger, Bajaj, P., Mueller, C., Triebel, F.
Format Journal Article
LanguageEnglish
Published 01.04.2023
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
DOI:10.1016/S1556-0864(23)00265-4